In line with our findings, FOSL1 activation has been identified as a prognostic marker in lung adenocarcinomas [69], and biomedical knowledge-based recommendations predict FOSL1 as a potential marker of osimertinib resistance [70]. Here, FOSL1 is linked to lung adenocarcinoma.